Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02343939 · ClinicalTrials.gov registry record · Phase 1
Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
A Phase 1 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT02343939 is a Phase 1 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 148 participants.
The verdict
NCT02343939, a Phase 1 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG Cytarabine
- DRUG Daunorubicin
- DRUG Entospletinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2015-07-01 |
| Est. Completion | 2019-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02343939
The ClinicalTrials.gov registry entry for NCT02343939 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Azacitidine is the first listed.
NCT02343939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02343939 about?
NCT02343939 is a clinical study titled "Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)". This study will evaluate the efficacy, safety, and tolerability of entospletinib when administered as monotherapy or in combination with chemotherapy in adults with acute myeloid leukemia (AML).
What is the current status of trial NCT02343939?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2015-07-01. Estimated completion is 2019-02-21.
What interventions are being tested in trial NCT02343939?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), Entospletinib (DRUG).
Who is sponsoring clinical trial NCT02343939?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.